Response of brain specific microenvironment to P-glycoprotein inhibitor: An important factor determining therapeutic effect of P-glycoprotein inhibitor on brain metastatic tumors

International Journal of Oncology

Volumn 33, Issue 4, 2008, Pages 705-712

  Joo, Kyeung Min ^a,b   Son, Sang Yong ^a   Park, Kwan ^a   Kim, Mi Hyun ^a,b   Jin, Juyoun ^a,b   Kang, Bong Gu ^a,b   Jang, Mi Jung ^a,b   Lee, Gwan Sun ^c   Kim, Maeng Sup ^c   Nam, Do Hyun ^a,b  

^a Samsung Medical Center   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Hanmi Pharmaceutical Co Ltd   (South Korea)

Author keywords

Brain metastasis; Brain microenvironment; Drug resistance; Endothelial cell; P glycoprotein

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; HM 30181A; PACLITAXEL; TARIQUIDAR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; BRAIN METASTASIS; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MELANOMA; MICROENVIRONMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOPYRANS; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOQUINOLINES; MALE; MICE; MICE, INBRED C3H; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; P-GLYCOPROTEIN; PACLITAXEL; TETRAZOLES;

EID: 54049101626     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000056     Document Type: Article

References (31)

1. Norden AD, Wen PY and Kesari S: Brain metastases. Curr Opin Neurol 18: 654-661, 2005.
2. Walker AE, Robins M, and Weinfeld FD: Epidemiology of brain tumors: the national survey of intracranial neoplasms. Neurology 35: 219-226, 1985.
3. Freilich RJ, Seidman AD and De Angelis LM: Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 76: 232-236, 1995.
4. Abbott N: Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 200: 527, 2002.
5. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR and Melamed MR: Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287, 1990.
6. Juliano RL and Ling V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 455: 152-162, 1976.
7. Kartner N, Riordan JR and Ling V: Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 22: 1285-1288, 1983.
8. Abbott NJ and Romero IA: Transporting therapeutics across the blood-brain barrier. Mol Med Today 2: 106-113, 1996.
9. Beaulieu E, Demeule M, Ghitescu L and Beliveau R: P-glycoprotein is strongly expressed in the luminal membranes of the endothelium of blood vessels in the brain. Biochem J 326: 539-544, 1997.
10. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM and Borst P: Disruption of the mouse mdrla P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502, 1994.
11. Schinkel AH, Wagenaar E, van Deemter L, Mol CA and Borst P: Absence of the mdrla P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 96: 1698-1705, 1995.
12. Van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P and van Tellingen O: Altered pharmacokinetics of vinblastine in Mdrla P-glycoprotein-deficient mice. J Natl Cancer Inst 88: 994-999, 1996.
13. Fellner S, Bauer B, Miller DS, Schaffrik M, Fankhänel M, Spruss T, Bernhardt G, Graeff C, Färber L, Gschaidmeier H, Buschauer A and Fricker G: Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo. J Clin Invest 110: 1309-1318, 2002.
14. Fidler IJ, Yano S, Zhang RD, Fujimaki T and Bucana CD: The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 3: 53-57, 2002.
15. Joo KM, Park K, Kong DS, Song SY, Kim MH, Lee GS, Kim MS and Nam DH: Oral paclitaxel chemotherapy for brain tumors: ideal combination treatment of paclitaxel and P-glycoprotein inhibitor. Oncol Rep 19: 17-23, 2008.
16. Nam DH, Park K, Park C, Im YH, Kim MH, Lee S, Hong SC, Shin HJ, Kim JH, Eoh W and McDonnell TJ: Intracranial inhibition of glioma cell growth by cyclooxygenase-2 inhibitor celecoxib. Oncol Rep 11: 263-268, 2004.
17. Paek IB, Ji HY, Kim MS, Lee GS and Lee HS: Simultaneous determination of paclitaxel and a new P-glycoprotein inhibitor HM-30181 in rat plasma by liquid chromatography with tandem mass spectrometry. J Sep Sci 29: 628-634, 2006.
18. Paek IB, Ji HY, Kim MS, Lee G and Lee HS: Metabolism of a new P-glycoprotein inhibitor HM-30181 in rats using liquid chromatography/ electrospray mass spectrometry. Rapid Commun Mass Spectrom 20: 1457-1462, 2006.
19. Thomas H and Coley HM: Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10: 159-165, 2003.
20. Calatozzolo C, Gelati M, Ciusani E, Sciacca FL, Pollo B, Cajola L, Marras C, Silvani A, Vitellaro-Zuccarello L, Croci D, Boiardi A and Salmaggi A: Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma. J Neurooncol 74: 113-121, 2005.
21. Tóth K, Vaughan MM, Peress NS, Slocum HK and Rustum YM: MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am J Pathol 149: 853-858, 1996.
22. Kemper EM, Boogerd W, Thuis I, Beijnen JH and van Tellingen O: Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumors? Cancer Treat Rev 30: 415-423, 2004.
23. Regina A, Demeule M, Laplante A, Jodoin J, Dagenais C, Berthelet F, Moghrabi A and Beliveau R: Multidrug resistance in brain tumors: roles of the blood-brain barrier. Cancer Metastasis Rev 20: 13-25, 2001.
24. Demeule M, Shedid D, Beaulieu E, Del Maestro RF, Moghrabi A, Ghosn PB, Moumdjian R, Berthelet F and Béliveau R: Expression of multidrug-resistance p-glycoprotein (MDR1) in human brain tumors. Int J Cancer 93: 62-66, 2001.
25. Zhang RD, Price JE, Fujimaki T, Bucana CD and Fidler IJ: Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 141: 1115-1124, 1992.
26. Roe M, Folkes A, Ashworth P, Brumwell J, Chima L, Hunjan S, Pretswell I, Dangerfield W, Ryder H and Charlton P: Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives. Bioorg Med Chem Lett 9: 595-600, 1999.
27. Dantzig AH, Shepard RL, Law KL, Tabas L, Pratt S, Gillespie JS, Binkley SN, Kuhfeld MT, Starling JJ and Wrighton SA: Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J Pharmacol Exp Ther 290: 854-862, 1999.
28. Van Zuylen L, Nooter K, Sparreboom A and Verweij J: Development of multidrug-resistance convertors: sense or nonsense? Invest New Drugs 18: 205-220, 2000.
29. Carlson RW, O'Neill AM, Goldstein LJ, Sikic BI, Abramson N, Stewart JA, Davidson NE and Wood WC: Eastern Cooperative Oncology Group, A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group. Cancer Invest 24: 677-681, 2006.
30. Newman MJ, Rodarte JC, Benbatoul KD, Romano SJ, Zhang C, Krane S, Moran EJ, Uyeda RT, Dixon R, Guns ES and Mayer LD: Discovery and characterization of OC144-093, a novel inhibitor of P-glycoproteinmediated multidrug resistance. Cancer Res 60: 2964-2972, 2000.
31. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G and Hortobagyi GN: Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104: 682-691, 2005.